Amcenestrant, a once-promising investigational optimized oral selective estrogen receptor degrader (SERD) from Sanofi (Nasdaq: SNY), did not meet the primary endpoint in a recent Phase 2 trial focused on advanced or metastatic breast cancer. Sanofi had previously referred to amcenestrant as a “potentially transformative” product. Investigators did not identify any new safety signals for the…